Figure 1

Waterfall plot of best responses, as percentage decrease in tumor size by RECIST, of the target lesions in patients. Fifty-five patients had measurable disease by RECIST and had at least 1 evaluation. The numbers above or below the bars represent the number of months the responders and patients with SD lasting ≥ 6 months received AST1306. * No EGFR or HER2 status; † EGFR exon 19/exon 20 double mutation; ‡ HER2 positive.